HK Stock Market Move | ASCLETIS-B (01672) has risen by more than 4% Company has completed communication with the National Medical Products Administration before submitting a new drug application for Dendyphothalascet.

ASCLETIS-B (01672) is currently up more than 4%, with a 4.29% increase at the time of writing, reaching 9.49 Hong Kong dollars, with a turnover of 23.5801 million Hong Kong dollars. In terms of news, Gilead Pharmaceuticals announced that it has recently communicated with the China National Medical Products Administration about the pre-new drug application of desmethylresveratrol (ASC40) for the treatment of moderate to severe acne vulgaris. They plan to submit a new drug application in the near future. The pre-communication for the new drug application (Pre-NDA) started in June 2025 and ended in October 2025. Furthermore, Gilead Pharmaceuticals recently announced that they have selected a promising monthly subcutaneous injection GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual agonist peptide ASC35 as a clinical development candidate. Gilead expects to submit an Investigational New Drug (IND) application for ASC35 for the treatment of obesity to the US Food and Drug Administration (FDA) in the second quarter of 2026. ASC35 is being developed as a monotherapy and combination therapy for the treatment of heart metabolic diseases, including obesity, diabetes, and metabolic dysfunction-associated fatty liver disease (MASH).